|
US20060035945A1
(en)
*
|
2003-05-30 |
2006-02-16 |
Giorgio Attardo |
Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases
|
|
AU2004242928B2
(en)
*
|
2003-05-30 |
2011-03-10 |
Gemin X Pharmaceuticals Canada Inc. |
Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases
|
|
EP1746888A2
(en)
*
|
2004-05-13 |
2007-01-31 |
Viropharma Incorporated |
Compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
|
|
JP5224818B2
(ja)
*
|
2004-12-28 |
2013-07-03 |
ジェミン エックス ファーマシューティカルズ カナダ インコーポレイテッド |
ジピロール化合物およびそれを含む医薬組成物
|
|
WO2006089397A1
(en)
*
|
2005-02-22 |
2006-08-31 |
Gemin X Biotechnologies Inc. |
Methods for treating arthritis using triheterocyclic compounds
|
|
US7994360B2
(en)
*
|
2005-05-16 |
2011-08-09 |
Xtl Biopharmaceuticals Ltd. |
Benzofuran compounds
|
|
US20080051400A1
(en)
*
|
2006-07-06 |
2008-02-28 |
Gemin X Biotechnologies Inc. |
Methods for treating or preventing anemia or thrombocytopenia using a triheterocyclic compound
|
|
MX2009006877A
(es)
|
2006-12-22 |
2009-09-28 |
Schering Corp |
Derivados indolicos con anillo unido en las posiciones 5,6 y metodos de uso de los mismos.
|
|
RU2009127855A
(ru)
|
2006-12-22 |
2011-01-27 |
Шеринг Корпорейшн (US) |
4,5 циклоаннелированные производные индола для лечения или предотвращения вируса гепатита с (hcv) и родственных вирусных инфекций
|
|
CA2673254C
(en)
|
2006-12-22 |
2013-09-10 |
Schering Corporation |
4,5-ring annulated indole derivatives for treating or preventing of hcv and related viral infections
|
|
EP2129473B1
(en)
*
|
2007-03-28 |
2019-07-03 |
Medtronic ATS Medical, Inc. |
Method for inhibiting platelet interaction with biomaterial surfaces
|
|
PE20090994A1
(es)
|
2007-08-29 |
2009-08-03 |
Schering Corp |
Derivados de azaindol 2,3-sustituidos como agentes antivirales
|
|
PE20090995A1
(es)
|
2007-08-29 |
2009-08-03 |
Schering Corp |
Derivados indolicos 2,3-sustituidos como inhibidores del virus de la hepatitis c (vhc)
|
|
CN101821252A
(zh)
|
2007-08-29 |
2010-09-01 |
先灵公司 |
取代的吲哚衍生物及其使用方法
|
|
CN101130539B
(zh)
*
|
2007-09-26 |
2012-05-30 |
浙江大学 |
吲哚取代咪唑啉-2-酮类衍生物及其制备方法和用途
|
|
US20090098118A1
(en)
|
2007-10-15 |
2009-04-16 |
Thomas Friess |
Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
|
|
WO2009064848A1
(en)
|
2007-11-16 |
2009-05-22 |
Schering Corporation |
3-heterocyclic substituted indole derivatives and methods of use thereof
|
|
WO2009064852A1
(en)
|
2007-11-16 |
2009-05-22 |
Schering Corporation |
3-aminosulfonyl substituted indole derivatives and methods of use thereof
|
|
CN102159579B
(zh)
|
2008-06-13 |
2015-03-25 |
默沙东公司 |
三环吲哚衍生物及其使用方法
|
|
CN103648491B
(zh)
*
|
2011-04-08 |
2017-07-14 |
法国国家健康医学研究院 |
用于抑制流感病毒复制的方法和药物组合物
|
|
US8946445B2
(en)
|
2011-10-12 |
2015-02-03 |
Nanjing Allgen Pharma Co., Ltd. |
Heterocyclic molecules as apoptosis inducers
|
|
WO2014100080A1
(en)
*
|
2012-12-19 |
2014-06-26 |
Glaxosmithkline Llc |
Combination
|
|
CN103044311B
(zh)
*
|
2012-12-26 |
2015-04-22 |
山东大学 |
一种多取代吲哚类化合物及其制备方法和应用
|
|
US20160022708A1
(en)
*
|
2013-03-14 |
2016-01-28 |
St. Jude Children's Research Hospital |
Methods and compositions for the treatment of glutamine-addicted cancers
|
|
ES2921874T3
(es)
|
2014-02-28 |
2022-09-01 |
Nimbus Lakshmi Inc |
Inhibidores de TYK2 y usos de los mismos
|
|
EP3139942B1
(en)
|
2014-05-05 |
2019-12-18 |
Bioventures, Llc |
COMPOSITIONS AND METHODS FOR INHIBITING ANTIAPOPTOTIC Bcl-2 PROTEINS AS ANTI-AGING AGENTS
|
|
AU2015292710A1
(en)
|
2014-07-22 |
2017-02-16 |
Bioventures, Llc. |
Compositions and methods for selectively depleting senescent cells
|
|
AU2015303835B2
(en)
|
2014-08-12 |
2020-04-09 |
Monash University |
Lymph directing prodrugs
|
|
US10532106B2
(en)
|
2014-10-29 |
2020-01-14 |
Bicyclerd Limited |
Bicyclic peptide ligands specific for MT1-MMP
|
|
TWI744225B
(zh)
|
2015-02-27 |
2021-11-01 |
美商林伯士拉克許米公司 |
酪胺酸蛋白質激酶２（ｔｙｋ２）抑制劑及其用途
|
|
ES2965461T3
(es)
|
2015-08-03 |
2024-04-15 |
Biokine Therapeutics Ltd |
Inhibidor de CXCR4 para el tratamiento del cáncer
|
|
EP4327809A3
(en)
|
2015-09-02 |
2024-04-17 |
Takeda Pharmaceutical Company Limited |
Tyk2 inhibitors and uses thereof
|
|
CA2997106C
(en)
|
2015-09-08 |
2024-06-04 |
Monash University |
Lymph directing prodrugs
|
|
US10683308B2
(en)
|
2015-09-11 |
2020-06-16 |
Navitor Pharmaceuticals, Inc. |
Rapamycin analogs and uses thereof
|
|
US20170087125A1
(en)
*
|
2015-09-30 |
2017-03-30 |
Augusta University Research Institute, Inc. |
Flavonoid compositions for the treatment of cancer
|
|
ES2941969T3
(es)
|
2015-10-23 |
2023-05-29 |
Navitor Pharm Inc |
Moduladores de la interacción de Sestrina-GATOR2 y sus usos
|
|
WO2017106352A1
(en)
|
2015-12-14 |
2017-06-22 |
Raze Therapeutics, Inc. |
Caffeine inhibitors of mthfd2 and uses thereof
|
|
HUE055197T2
(hu)
|
2016-03-09 |
2021-11-29 |
Raze Therapeutics Inc |
3-Foszfoglicerát-dehidrogenáz inhibitorok és alkalmazásuk
|
|
WO2017156179A1
(en)
|
2016-03-09 |
2017-09-14 |
Raze Therapeutics, Inc. |
3-phosphoglycerate dehydrogenase inhibitors and uses thereof
|
|
SG11201807965YA
(en)
|
2016-03-15 |
2018-10-30 |
Oryzon Genomics Sa |
Combinations of lsd1 inhibitors for use in the treatment of solid tumors
|
|
KR102511028B1
(ko)
|
2016-03-15 |
2023-03-16 |
오리존 지노믹스 에스.에이. |
혈액 악성 종양의 치료를 위한 lsd1 억제제의 조합물
|
|
WO2017177216A1
(en)
*
|
2016-04-08 |
2017-10-12 |
Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center |
Prodigiosin analogs
|
|
CA3019394A1
(en)
|
2016-04-08 |
2017-10-12 |
X4 Pharmaceuticals, Inc. |
Methods for treating cancer
|
|
US10870640B2
(en)
|
2016-04-08 |
2020-12-22 |
Institute For Cancer Research |
Prodigiosin analogs and methods of use
|
|
KR102447884B1
(ko)
|
2016-04-21 |
2022-09-27 |
바이오벤처스, 엘엘씨 |
항-세포자멸적 bcl-2 계열 단백질의 열화를 유도하는 화합물 및 이의 용도
|
|
CN109562106B
(zh)
|
2016-06-21 |
2023-03-21 |
X4 制药有限公司 |
Cxcr4抑制剂及其用途
|
|
CN109640988A
(zh)
|
2016-06-21 |
2019-04-16 |
X4 制药有限公司 |
Cxcr4抑制剂及其用途
|
|
EP3848370B1
(en)
|
2016-10-14 |
2025-05-07 |
Takeda Pharmaceutical Company Limited |
Tyk2 inhibitors and uses thereof
|
|
IL266109B2
(en)
|
2016-10-21 |
2025-05-01 |
Nimbus Lakshmi Inc |
Tyk2 inhibitors and uses thereof
|
|
EP3538091A4
(en)
|
2016-11-08 |
2020-06-10 |
Navitor Pharmaceuticals, Inc. |
PHENYL AMINO PIPERIDINE MTORC INHIBITORS AND USES THEREOF
|
|
AU2017368050A1
(en)
|
2016-11-29 |
2019-06-20 |
Puretech Lyt, Inc. |
Exosomes for delivery of therapeutic agents
|
|
WO2018106636A1
(en)
|
2016-12-05 |
2018-06-14 |
Raze Therapeutics, Inc. |
Shmt inhibitors and uses thereof
|
|
US10624968B2
(en)
|
2017-01-06 |
2020-04-21 |
Bicyclerd Limited |
Compounds for treating cancer
|
|
IL269036B2
(en)
|
2017-03-08 |
2023-03-01 |
Nimbus Lakshmi Inc |
tyk2 inhibitors, uses and methods for their production
|
|
EP3375778A1
(en)
|
2017-03-14 |
2018-09-19 |
Artax Biopharma Inc. |
Aryl-piperidine derivatives
|
|
EP3375784A1
(en)
|
2017-03-14 |
2018-09-19 |
Artax Biopharma Inc. |
Aza-dihydro-acridone derivatives
|
|
US11339144B2
(en)
|
2017-04-10 |
2022-05-24 |
Navitor Pharmaceuticals, Inc. |
Heteroaryl Rheb inhibitors and uses thereof
|
|
ES3040534T3
(en)
|
2017-04-26 |
2025-11-03 |
Navitor Pharm Inc |
Modulator of sestrin-gator2 interaction for use in the treatment of treatment-resistant depression
|
|
EP3658557B1
(en)
|
2017-07-28 |
2024-06-05 |
Takeda Pharmaceutical Company Limited |
Tyk2 inhibitors and uses thereof
|
|
CN111183147B
(zh)
|
2017-08-04 |
2024-07-05 |
拜斯科技术开发有限公司 |
Cd137特异性的双环肽配体
|
|
EP3675838A4
(en)
|
2017-08-29 |
2021-04-21 |
PureTech LYT, Inc. |
LIPID PRODRUGS DIRECTED TO THE LYMPHATIC SYSTEM
|
|
US11883497B2
(en)
|
2017-08-29 |
2024-01-30 |
Puretech Lyt, Inc. |
Lymphatic system-directing lipid prodrugs
|
|
WO2019060742A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc |
AGENTS FOR DEGRADING PROTEINS AND USES THEREOF
|
|
EP3684366A4
(en)
|
2017-09-22 |
2021-09-08 |
Kymera Therapeutics, Inc. |
CRBN LIGANDS AND USES OF THE LATEST
|
|
EP3727362A4
(en)
|
2017-12-19 |
2021-10-06 |
PureTech LYT, Inc. |
MYCOPHENOLIC ACID LIPID PRODRUGS AND THEIR USES
|
|
US11304954B2
(en)
|
2017-12-19 |
2022-04-19 |
Puretech Lyt, Inc. |
Lipid prodrugs of mycophenolic acid and uses thereof
|
|
US11608345B1
(en)
|
2017-12-19 |
2023-03-21 |
Puretech Lyt, Inc. |
Lipid prodrugs of rapamycin and its analogs and uses thereof
|
|
IL315310A
(en)
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
WO2019140380A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
EP3737675A4
(en)
|
2018-01-12 |
2022-01-05 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
|
JP7385284B2
(ja)
|
2018-01-22 |
2023-11-22 |
バイオベンチャーズ・リミテッド・ライアビリティ・カンパニー |
癌処置のためのｂｃｌ－２タンパク質分解剤
|
|
SG11202006701TA
(en)
|
2018-01-29 |
2020-08-28 |
Merck Patent Gmbh |
Gcn2 inhibitors and uses thereof
|
|
IL312674A
(en)
|
2018-01-29 |
2024-07-01 |
Merck Patent Gmbh |
GCN2 inhibitors and uses thereof
|
|
JP2021514953A
(ja)
|
2018-02-23 |
2021-06-17 |
バイスクルテクス・リミテッド |
多量体二環式ペプチドリガンド
|
|
CA3091202A1
(en)
|
2018-02-27 |
2019-09-06 |
Artax Biopharma Inc. |
Chromene derivatives as inhibitors of tcr-nck interaction
|
|
IL278122B2
(en)
|
2018-04-24 |
2024-01-01 |
Vertex Pharma |
Pteridinone compounds and uses thereof
|
|
ES2987356T3
(es)
|
2018-04-24 |
2024-11-14 |
Merck Patent Gmbh |
Compuestos antiproliferación y usos de los mismos
|
|
WO2019221755A1
(en)
|
2018-05-18 |
2019-11-21 |
Bioventures, Llc |
Piperlongumine analogues and uses thereof
|
|
SG11202012447YA
(en)
|
2018-06-15 |
2021-01-28 |
Navitor Pharm Inc |
Rapamycin analogs and uses thereof
|
|
US11180531B2
(en)
|
2018-06-22 |
2021-11-23 |
Bicycletx Limited |
Bicyclic peptide ligands specific for Nectin-4
|
|
WO2020010227A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
US11292792B2
(en)
|
2018-07-06 |
2022-04-05 |
Kymera Therapeutics, Inc. |
Tricyclic CRBN ligands and uses thereof
|
|
US10548889B1
(en)
|
2018-08-31 |
2020-02-04 |
X4 Pharmaceuticals, Inc. |
Compositions of CXCR4 inhibitors and methods of preparation and use
|
|
EP3846793B1
(en)
|
2018-09-07 |
2024-01-24 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
|
WO2020081508A1
(en)
|
2018-10-15 |
2020-04-23 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
|
CN113164414A
(zh)
|
2018-10-24 |
2021-07-23 |
纳维托制药有限公司 |
多晶型化合物和其用途
|
|
WO2020112937A1
(en)
|
2018-11-30 |
2020-06-04 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
|
US11352350B2
(en)
|
2018-11-30 |
2022-06-07 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
|
GB201820288D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicycle Tx Ltd |
Bicycle peptide ligaands specific for MT1-MMP
|
|
GB201820295D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for MT1-MMP
|
|
GB201820325D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for psma
|
|
EP3670659A1
(en)
|
2018-12-20 |
2020-06-24 |
Abivax |
Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
|
|
WO2020128526A1
(en)
|
2018-12-21 |
2020-06-25 |
Bicycletx Limited |
Bicyclic peptide ligands specific for pd-l1
|
|
AU2020212001A1
(en)
|
2019-01-23 |
2021-07-22 |
Takeda Pharmaceutical Company Limited |
TYK2 inhibitors and uses thereof
|
|
JP2022528887A
(ja)
|
2019-04-02 |
2022-06-16 |
バイスクルテクス・リミテッド |
バイシクルトキシンコンジュゲートおよびその使用
|
|
SG11202110829YA
(en)
|
2019-04-05 |
2021-10-28 |
Kymera Therapeutics Inc |
Stat degraders and uses thereof
|
|
KR20220034739A
(ko)
|
2019-05-31 |
2022-03-18 |
이케나 온콜로지, 인코포레이티드 |
Tead 억제제 및 이의 용도
|
|
EP4028385A4
(en)
|
2019-09-11 |
2023-11-08 |
Vincere Biosciences, Inc. |
USP30 INHIBITORS AND USES THEREOF
|
|
US12215105B2
(en)
|
2019-09-13 |
2025-02-04 |
Nimbus Saturn, Inc. |
HPK1 antagonists and uses thereof
|
|
IL292612A
(en)
|
2019-11-01 |
2022-07-01 |
Navitor Pharm Inc |
Treatment methods using mtorc1 modulator
|
|
TW202134234A
(zh)
|
2019-12-05 |
2021-09-16 |
美商奈維特製藥公司 |
雷帕黴素類似物及其用途
|
|
WO2021127283A2
(en)
|
2019-12-17 |
2021-06-24 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
EP4076520A4
(en)
|
2019-12-17 |
2024-03-27 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
BR112022012410A2
(pt)
|
2019-12-23 |
2022-08-30 |
Kymera Therapeutics Inc |
Degradadores smarca e usos dos mesmos
|
|
WO2021159021A1
(en)
|
2020-02-05 |
2021-08-12 |
Puretech Lyt, Inc. |
Lipid prodrugs of neurosteroids
|
|
BR112022017727A2
(pt)
|
2020-03-03 |
2022-11-16 |
Pic Therapeutics Inc |
Inibidores de eif4e e usos dos mesmos
|
|
PH12022552458A1
(en)
|
2020-03-19 |
2024-01-22 |
Kymera Therapeutics Inc |
Mdm2 degraders and uses thereof
|
|
US20230250110A1
(en)
|
2020-06-03 |
2023-08-10 |
Kymera Therapeutics, Inc. |
Deuterated irak degraders and uses thereof
|
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
|
CN116133692A
(zh)
|
2020-07-30 |
2023-05-16 |
凯麦拉医疗公司 |
治疗突变淋巴瘤的方法
|
|
KR20230074721A
(ko)
|
2020-08-17 |
2023-05-31 |
바이사이클티엑스 리미티드 |
Nectin-4에 특이적인 이환 콘쥬게이트 및 이의 용도
|
|
EP4232425A4
(en)
|
2020-10-23 |
2024-07-24 |
Nimbus Clotho, Inc. |
Ctps1 inhibitors and uses thereof
|
|
WO2022120353A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
CA3200814A1
(en)
|
2020-12-02 |
2022-06-09 |
Alfredo C. Castro |
Tead inhibitors and uses thereof
|
|
AU2021393753A1
(en)
*
|
2020-12-03 |
2023-06-22 |
Enyo Pharma |
Pyrrole-type compounds and uses thereof for treating viral infections
|
|
EP4008324A1
(en)
|
2020-12-07 |
2022-06-08 |
Cellestia Biotech AG |
Combinations comprising an inhibitor of an anti-apoptotic protein, such as bcl-2, bcl-xl, bclw or mcl-1, and a notch signaling pathway inhibitor for treating cancer
|
|
EP4255409A1
(en)
|
2020-12-07 |
2023-10-11 |
Cellestia Biotech AG |
Pharmaceutical combinations for treating cancer
|
|
TW202241891A
(zh)
|
2020-12-30 |
2022-11-01 |
美商凱麥拉醫療公司 |
Irak降解劑及其用途
|
|
KR20230152692A
(ko)
|
2021-02-02 |
2023-11-03 |
리미널 바이오사이언시스 리미티드 |
Gpr84 길항제 및 이의 용도
|
|
EP4288427A1
(en)
|
2021-02-02 |
2023-12-13 |
Liminal Biosciences Limited |
Gpr84 antagonists and uses thereof
|
|
US12252488B2
(en)
|
2021-02-12 |
2025-03-18 |
Nimbus Saturn, Inc. |
HPK1 antagonists and uses thereof
|
|
IL304905A
(en)
|
2021-02-15 |
2023-10-01 |
Kymera Therapeutics Inc |
IRAK4 joints and their uses
|
|
JP2024506656A
(ja)
|
2021-02-15 |
2024-02-14 |
カイメラ セラピューティクス， インコーポレイテッド |
Ｉｒａｋ４分解剤およびその使用
|
|
WO2022187856A1
(en)
|
2021-03-05 |
2022-09-09 |
Nimbus Saturn, Inc. |
Hpk1 antagonists and uses thereof
|
|
US12071442B2
(en)
|
2021-03-29 |
2024-08-27 |
Nimbus Saturn, Inc. |
Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists
|
|
WO2022217276A1
(en)
|
2021-04-09 |
2022-10-13 |
Nimbus Clio, Inc. |
Cbl-b modulators and uses thereof
|
|
AU2022258968A1
(en)
|
2021-04-16 |
2023-10-19 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
US12097261B2
(en)
|
2021-05-07 |
2024-09-24 |
Kymera Therapeutics, Inc. |
CDK2 degraders and uses thereof
|
|
JP2024534127A
(ja)
|
2021-08-25 |
2024-09-18 |
ピク セラピューティクス， インコーポレイテッド |
ｅＩＦ４Ｅ阻害剤及びその使用
|
|
EP4392421A1
(en)
|
2021-08-25 |
2024-07-03 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
|
WO2023076556A1
(en)
|
2021-10-29 |
2023-05-04 |
Kymera Therapeutics, Inc. |
Irak4 degraders and synthesis thereof
|
|
US20250154141A1
(en)
|
2021-12-09 |
2025-05-15 |
University Of Florida Research Foundation, Incorporated |
Bcl-xl/bcl-2 dual degraders for treatment of cancers
|
|
WO2023114984A1
(en)
|
2021-12-17 |
2023-06-22 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
JP2025504059A
(ja)
|
2022-01-31 |
2025-02-06 |
カイメラ セラピューティクス， インコーポレイテッド |
Ｉｒａｋデグレーダー及びその使用
|
|
WO2023173057A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
WO2023173053A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
WO2023211889A1
(en)
|
2022-04-25 |
2023-11-02 |
Ikena Oncology, Inc. |
Polymorphic compounds and uses thereof
|
|
US11878958B2
(en)
|
2022-05-25 |
2024-01-23 |
Ikena Oncology, Inc. |
MEK inhibitors and uses thereof
|
|
JP2025527248A
(ja)
|
2022-08-02 |
2025-08-20 |
リミナル・バイオサイエンシーズ・リミテッド |
置換ピリドンｇｐｒ８４アンタゴニスト及びその使用
|
|
WO2024028364A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Aryl-triazolyl and related gpr84 antagonists and uses thereof
|
|
EP4565568A1
(en)
|
2022-08-02 |
2025-06-11 |
Liminal Biosciences Limited |
Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
|
|
US20240208961A1
(en)
|
2022-11-22 |
2024-06-27 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
|
IL321486A
(en)
|
2023-06-23 |
2025-08-01 |
Kymera Therapeutics Inc |
Iraqi joints and their uses
|
|
TW202529769A
(zh)
|
2023-09-21 |
2025-08-01 |
日商武田藥品工業股份有限公司 |
Ｔｙｋ２抑制劑及其用途
|
|
WO2025132801A1
(en)
|
2023-12-19 |
2025-06-26 |
Cimeio Therapeutics Ag |
Discernible protein variants of bcl-2 for use in cell therapy
|